[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-transplantation-lt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-transplantation-lt":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,74,103,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100649328","mental-health-outcomes-and-psychological-evaluation-after-liver-transplantation-100649328",false,"NCT07734142","Mental Health Outcomes and Psychological Evaluation After Liver Transplantation","mHOPE","Inclusion Criteria:\n\n* Adults (≥18 years of age)\n* Having undergone a single liver transplantation during adulthood at Pitié-Salpêtrière Hospital\n* Attending a post-transplant follow-up consultation at Pitié-Salpêtrière Hospital 5 to 10 years after liver transplantation\n* Proficiency in the French language, required to complete the questionnaires\n* Able to write and physically capable of completing written questionnaires\n\nExclusion Criteria:\n\n* Patients who have undergone a second liver transplantation (re-transplantation)\n* Patients who have received a combined organ transplant\n* Adults under legal guardianship or curatorship\n* Patients deprived of their liberty by judicial or administrative decision\n* Refusal to participate in the study","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","OBSERVATIONAL","Receiving a liver transplant is a major life event that can be physically and emotionally challenging. During the first five years after transplantation, more than one in two liver transplant recipients experience a mental health disorder. These disorders may reduce adherence to treatment, increase the risk of graft rejection, impair quality of life, and, in some cases, increase the risk of death. Depression is the most common mental health disorder, affecting approximately one in four liver transplant recipients.\n\nSurvival after liver transplantation has improved considerably over recent decades. However, little is known about the long-term mental health of liver transplant recipients. Routine follow-up visits after transplantation play an important role by strengthening the relationship between patients and the healthcare team and by providing regular opportunities to assess mental well-being in addition to standard transplant follow-up, such as monitoring liver health, screening for cancer and cardiovascular disease, and managing treatment-related complications. These visits also help identify the need for additional support, such as addiction specialists, dietitians, or other healthcare professionals, and provide an opportunity to detect symptoms of depression, particularly in patients experiencing personal or family difficulties.\n\nBeyond routine medical follow-up, there is a growing need to better understand mental health many years after liver transplantation. Learning from patients' experiences may help improve the early detection, prevention, and management of depression and other mental health disorders.\n\nThe primary objective of this study is to determine the prevalence of moderate-to-severe depressive symptoms among adult liver transplant recipients who underwent transplantation more than five years ago.",[24],"Liver Transplantation (LT)",[26,27,28,29],"Liver Transplantation","Depression","Anxiety","Alcohol-Related Liver Disease","NOT_YET_RECRUITING","2026-07-23",{"date":33,"type":34},"2026-07-29","ACTUAL",{"date":36,"type":20},"2026-10",{"date":38,"type":20},"2028-10",{"name":40,"class":41},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100645692","avoiding-recooling-after-normothermic-machine-perfusion-in-liver-transplantation-100645692","NCT07692490","Avoiding Recooling After Normothermic Machine Perfusion in Liver Transplantation","Avoiding Recooling After Normothermic Machine Perfusion in Liver Transplantation: a Multicenter, Parallel-group, Open-label, Non-inferiority Randomized Controlled Trial","ARANMP-LT","Inclusion Criteria:\n\n* Age ≥18 years.\n* Listed for primary liver transplantation at the participating institution.\n* Assigned a liver graft preserved with normothermic machine perfusion or sequential hypothermic- normothermic machine perfusion (SHNMP).\n* Signed and dated informed consent prior study inclusion.\n\nExclusion Criteria:\n\n* Pediatric patients (age \\\u003C 18 years)\n* Patients undergoing re-transplantation (history of previous liver transplantation)\n* Patients with acute liver failure\n* Patients undergoing multi-organ transplantation (e.g., liver-kidney, liver-heart)\n* Temporarily unconscious patients\n* Patients unable to freely express consent.",{"count":51,"type":20},170,"INTERVENTIONAL",[54],"NA","The ARANMP-LT study is a multicenter, open-label, randomized, parallel-group, non-inferiority clinical trial designed to evaluate whether avoiding graft recooling after normothermic machine perfusion (NMP) improves early outcomes following liver transplantation. Although graft recooling before implantation is common practice, experimental and preliminary clinical evidence suggests that abrupt temperature changes may contribute to ischemia-reperfusion injury.\n\nAdult recipients of deceased-donor liver grafts preserved with NMP or sequential hypothermic-normothermic machine perfusion (SHNMP) will be randomized in a 1:1 ratio to either standard graft implantation with recooling using cold preservation solution (control group) or implantation without recooling using a room-temperature 5% albumin flush immediately before reperfusion (intervention group).\n\nThe primary objective is to compare the incidence of Early Allograft Dysfunction (EAD), defined according to the Olthoff criteria, between the two treatment groups. Secondary objectives include evaluation of histopathological ischemia-reperfusion injury using the Suzuki score, vascular and biliary complications, primary non-function, post-reperfusion syndrome, patient and graft survival, length of intensive care unit and hospital stay, perioperative transfusion requirements, and safety outcomes. A total of 170 participants will be enrolled across multiple Italian liver transplant centers and followed for 90 days after transplantation.",[24,57,58],"Ischemia-Reperfusion Injury","Early Allograft Dysfunction",[26,60,57,58,61,62],"Normothermic Machine Perfusion","Organ Preservation","Liver Graft","RECRUITING","2026-07-10",{"date":66,"type":34},"2026-07-14",{"date":68,"type":20},"2026-07-07",{"date":70,"type":20},"2028-10-06",{"name":72,"class":41},"The Mediterranean Institute for Transplantation and Advanced Specialized Therapies",14,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":52,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100646057","restrictive-fluid-management-in-liver-transplantation-refil-100646057","NCT07695363","Restrictive Fluid Management In Liver Transplantation (REFIL)","Effects of an Intraoperative Low-splanchnic Blood Volume Restrictive Fluid Management Strategy Compared to a Cardiac Output Optimized Liberal Fluid Management Strategy on Postoperative Outcomes in Liver Transplantation: A Multicenter Randomized Controlled Trial (REFIL-2)","REFIL-2","Inclusion Criteria:\n\n1. Adult ≥ 18 years old\n2. Undergoing liver transplantation (LT)\n3. End-stage liver disease (ESLD) (with or without hepatocellular carcinoma) as the indication for transplantation.\n\nExclusion Criteria:\n\n1. Undergoing LT for an indication other than ESLD (e.g., acute liver failure, primary liver cancer without ESLD, retransplantation, amyloid neuropathy, polycystic liver disease, or any other indication not associated with ESLD)\n2. Undergoing combined solid organ transplantations\n3. Any of the following conditions:\n\n   * severe chronic renal failure (GFR \\\u003C 15 ml\u002Fminute\u002F1.73 m2 \\[CKD-EPI equation\\] or already on renal replacement therapy (RRT))\n   * severe anemia (hemoglobin level \\\u003C 80 g\u002FL)\n   * hemodynamic instability (norepinephrine equivalent \\> 10 ug\u002Fmin)\n4. Physician refusal to enroll the patient.",{"count":83,"type":20},866,[54],"The goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications that raise blood pressure during surgery, combined with phlebotomy) in improving patients' recovery after surgery. The study compares the low splanchnic blood volume restrictive fluid management strategy to an optimized cardiac-output liberal fluid management strategy (which involves administering more fluids to raise blood pressure with less reliance on medications). Outcomes important to patients will be measured.\n\nThis study (REFIL-2) had a vanguard phase (internal pilot) that included 138 patients (NCT05647733). The patients included in the vanguard pilot phase were not compared between groups but only analyzed descriptively using aggregated data. Only feasibility metrics were compared (see NCT05647733). These 138 patients were thus rolled into the REFIL-2 trial and included in the final sample size reported herein.",[24,87],"End-stage Liver Disease (ESLD)",[26,89,90,91,92,93],"Phlebotomy","Hemodynamic Management","Fluid Management","Transfusions","Liver Diseases","2026-07-08",{"date":64,"type":34},{"date":97,"type":34},"2026-02-15",{"date":99,"type":20},"2031-11",{"name":101,"class":41},"Centre hospitalier de l'Université de Montréal (CHUM)",4,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":52,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100644712","new-biomarkers-for-organ-viability-assessment-during-hypothermic-machine-perfusion-in-liver-transplantation-the-role-of-extemporaneous-histological-examination-100644712","NCT07674394","New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.","LOVE","Inclusion Criteria:\n\n1. Adult liver transplant recipients (≥18 years of age).\n2. Donor liver grafts from either Donation after Brain Death (DBD) or Donation after Circulatory Death (DCD).\n3. Grafts undergoing hypothermic oxygenated perfusion (HOPE) (HOPE or D-HOPE) for a minimum duration of 1 hour prior to transplantation.\n4. Availability of two wedge liver biopsy samples: one pre perfusion and one post-perfusion.\n5. Grafts preserved using standard cold storage protocols and transported in ice-cold Servator C™ solution.\n6. Informed consent obtained from the recipient (or legal representative, where applicable) for the use of clinical and histological data for research purposes.\n\nExclusion Criteria:\n\n1. Inadequate or fragmented biopsy samples, preventing proper histological evaluation.\n2. Biopsy samples showing histological features of pre-existing chronic liver disease (e.g., cirrhosis, autoimmune hepatitis, chronic viral hepatitis).\n3. Liver grafts subjected to normothermic perfusion or other non hypothermic perfusion techniques.\n4. Organs undergoing experimental or non-standard perfusion protocols.\n5. Grafts from donors \\\u003C18 years of age.\n6. Recipient refusal or inability to provide informed consent.\n7. Technical failure during perfusion (e.g., incomplete perfusion due to device malfunction or vascular anomalies).\n8. Known malignancy in the donor with potential liver involvement, excluding donors with small incidentalomas as per standard guidelines.",{"count":111,"type":20},150,[54],"Liver transplantation is a life-saving treatment for patients with severe liver disease. Because of the shortage of donor organs, transplant centers increasingly use donor livers that may be more vulnerable to injury and dysfunction. To improve the quality of these organs before transplantation, many centers use hypothermic oxygenated machine perfusion (HOPE or D-HOPE), a technique that preserves the liver under cold, oxygenated conditions. However, there are currently no widely accepted methods to determine whether a liver is functioning well enough during this preservation process.\n\nThe purpose of this study is to investigate whether changes observed in liver tissue during hypothermic machine perfusion can help predict how well the transplanted liver will function after surgery. The study will compare liver biopsy samples collected before and after one hour of perfusion and will analyze biological markers released into the perfusion fluid, including markers of mitochondrial injury and inflammation.\n\nThe main question this study aims to answer is whether histological changes occurring during hypothermic perfusion, alone or in combination with biochemical biomarkers, can accurately predict liver graft viability and post-transplant outcomes. Researchers will also evaluate whether these data can be used to develop an artificial intelligence-based model to support clinical decision-making during organ preservation.\n\nA total of 150 adult liver transplant recipients receiving donor livers treated with HOPE or D-HOPE will be enrolled at three Italian liver transplant centers. Participants will be followed for 90 days after transplantation to assess liver graft function, graft survival, patient survival, and post-transplant complications.\n\nThe results of this study may improve the assessment of donor liver quality before transplantation and help clinicians make more informed decisions about organ use, ultimately increasing the safety and effectiveness of liver transplantation.",[24,58,115,57],"Primary Non-function",[117,118,119,57,120],"liver transplantation","Early Allograft Dysfunction (EAD)","Primary Non-Function (PNF)","Liver Graft Viability Assessment","2026-06-23",{"date":123,"type":34},"2026-06-29",{"date":125,"type":20},"2026-07",{"date":127,"type":20},"2029-06",{"name":72,"class":41},3,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100640838","liver-transplant-for-hepatocellular-carcinoma-100640838","NCT07629193","Liver Transplant for Hepatocellular Carcinoma","TH-CHC","Inclusion Criteria\n\n1. Adults (≥18 years).\n2. Underwent LT for HCC between January 1, 2018 and December 31, 2023.\n\nExclusion Criteria\n\n1. No evidence of HCC (imaging or histology).\n2. LT performed for another intrahepatic tumor other than HCC.\n3. The patient's objection to the use of their data.",{"count":138,"type":20},562,"This research focuses on analysing data collected as part of your usual care. Currently, the eligibility of patients with hepatocellular carcinoma for liver transplantation is based on the calculation of scores. These scores mainly take into account the volume of the tumour measured by imaging, one or more blood markers and the patient's general condition.\n\nHowever, these scores do not take into account:\n\n* the concept of downstaging (i.e. the prior reduction of tumour volume through locoregional or systemic treatments, which subsequently allows access to LT), which is becoming increasingly widespread\n* the dynamics of hepatocellular carcinoma (tumour recurrence while waiting on the transplant list, administration of wait-and-see treatments)\n* certain anatomopathological parameters (such as the macro-trabecular subtype of HCC).\n\nThe aim of our study is to develop a new score incorporating these factors in order to identify patients with hepatocellular carcinoma who could truly benefit from a liver transplant.\n\nTo answer the question posed in the research, data will be collected from 402 people who received a liver transplant for hepatocellular carcinoma at three hospitals in the Paris region between 1 January 2018 and 31 December 2023, and from 160 people at two international hospitals in Canada and Belgium.",[141,24],"Hepatocellular Carcinoma (HCC)",[143,24],"predictive score","2026-06-01",{"date":146,"type":34},"2026-06-05",{"date":148,"type":20},"2026-06",{"date":150,"type":20},"2027-01",{"name":40,"class":41}]